Distinguished in Astrocytoma

Emeline Tabouret

Marseille, FR 
Distinguished in Astrocytoma
Marseille, FR 
OverviewLocationsClinical Research

Overview

Emeline Tabouret practices in Marseille, France. Ms. Tabouret is rated as a Distinguished expert by MediFind in the treatment of Astrocytoma. Her top areas of expertise are Glioma, Gliomatosis Cerebri, Astrocytoma, Glioblastoma, and Vitrectomy.

Her clinical research consists of co-authoring 115 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 39 articles in the study of Astrocytoma.

Gender
Female

Locations

Marseille, 13005, France
Other Locations
Paris, France
2, Avenue Martin Luther King, Limoges, 87000, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Study of the Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy
Study of the Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy
Enrollment Status: Withdrawn
Publish Date: June 27, 2022
Intervention Type: Drug
Study Phase: Not Applicable
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway
An International, Randomized, Open-label Phase I/II Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Adult Patients With Recurrent or Refractory Medulloblastomas Presenting an Activation of the Sonic Hedgehog (SHH) Pathway
Enrollment Status: Terminated
Publish Date: May 21, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

115 Total Publications

Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935.
Correction: Tabouret et al. TP5, a Peptide Inhibitor of Aberrant and Hyperactive CDK5/p25: A Novel Therapeutic Approach against Glioblastoma. Cancers 2020, 12, 1935.
Journal: Cancers
Published: September 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Tabouret's expertise for a condition
ConditionClose
    View All 16 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile